Literature DB >> 7873602

Isolation and molecular cloning of human sorcin a calcium-binding protein in vincristine-resistant HOB1 lymphoma cells.

S L Wang1, M F Tam, Y S Ho, S H Pai, M C Kao.   

Abstract

A vincristine-resistant lymphoma cell line (HOB1/VCR1.0) that is resistant to 1.0 microM of vincristine has been established from a human immunoblastic B lymphoma cell line, HOB1. HOB1/VCR1.0 cells demonstrated the typical multidrug resistant phenotypes. Using two-dimensional gel electrophoresis, we discovered one protein with a molecular mass of 22 kDa and pI 5.7 that was overexpressed in HOB1/VCR1.0 cells. This protein was purified to the degree of apparent homogeneity by preparative isoelectric focusing and sodium dodecylsulfate-polyacrylamide gel electrophoresis. The identification of this protein with sorcin was revealed by comparing the internal amino acid sequence of three Lys-C digested peptides from the purified protein with the sequence previously determined for hamster sorcin. The complete primary structure of the human sorcin was deduced from nucleotide sequence analysis of its cDNA clones. It is composed of 198 amino acid residues with a calculated molecular weight of 21,676, and its sequence is highly similar to that of hamster sorcin (95%). Direct-binding assay with calcium showed that human sorcin is a calcium-binding protein with four 'E-F hand' structures typical of calcium-binding sites. Like the sorcin of hamster, two of the calcium-binding sites of human sorcin contain putative recognition sites for cAMP-dependent protein kinase. Southern and Northern blot analyses showed that the human sorcin gene was greatly amplified and overexpressed in resistant HOB1/VCR1.0 cells but not detected in the parental HOB1 cells. The overproduction of this protein in resistant cells implies that sorcin plays a role in expression of the resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7873602     DOI: 10.1016/0167-4781(94)00206-i

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Sorcin, a potential therapeutic target for reversing multidrug resistance in cancer.

Authors:  Bei-Bei Zheng; Peng Zhang; Wei-Wei Jia; Lu-Gang Yu; Xiu-Li Guo
Journal:  J Physiol Biochem       Date:  2012-06       Impact factor: 4.158

2.  Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2).

Authors:  A R Alexanian; N S Arutyunian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Crystal structure of calcium-free human sorcin: a member of the penta-EF-hand protein family.

Authors:  X Xie; M D Dwyer; L Swenson; M H Parker; M C Botfield
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

4.  New insights into TRAP1 pathway.

Authors:  Danilo Swann Matassa; Maria Rosaria Amoroso; Francesca Maddalena; Matteo Landriscina; Franca Esposito
Journal:  Am J Cancer Res       Date:  2012-02-19       Impact factor: 6.166

5.  Overexpression of sorcin in multidrug-resistant human breast cancer.

Authors:  Zhaohua Gong; Ping Sun; Hongjin Chu; Hua Zhu; Dengjun Sun; Jian Chen
Journal:  Oncol Lett       Date:  2014-09-17       Impact factor: 2.967

Review 6.  Sorcin a Potential Molecular Target for Cancer Therapy.

Authors:  Bano Shabnam; Ganesan Padmavathi; Kishore Banik; Sosmitha Girisa; Javadi Monisha; Gautam Sethi; Lu Fan; Lingzhi Wang; Xinliang Mao; Ajaikumar B Kunnumakkara
Journal:  Transl Oncol       Date:  2018-09-11       Impact factor: 4.243

7.  Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells.

Authors:  Ilaria Genovese; Annarita Fiorillo; Andrea Ilari; Silvia Masciarelli; Francesco Fazi; Gianni Colotti
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

8.  Sorcin: a novel potential target in therapies of cancers.

Authors:  Xinyi Zhou; Xue Wu; Baoan Chen
Journal:  Cancer Manag Res       Date:  2019-08-05       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.